INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...

INDICATION: Pain Cell culture and mouse studies identified a TRPM8 antagonist that could help treat pain. Chemical synthesis of dibenzyl tryptamine analogs and HEK cell-based ion channel assays yielded a compound that inhibited TRPM8 with...

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...

RaQualia Pharma Inc. (JASDAQ:4579) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia will receive an undisclosed upfront payment and is eligible for development...

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...

Asahi and RaQualia partnered to discover pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia will receive an undisclosed research collaboration payment and will be eligible for undisclosed...

RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover and develop analgesic compounds. The partners will use multiple lead identification approaches, including high throughput screening, to identify compounds...

CJ Group’s CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ will receive an upfront payment and is eligible for clinical, regulatory and performance-based milestones plus double-digit royalties....

Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine diseases including Cushing's disease. Ipsen will have an exclusive option to license candidates developed during the partnership. Interprotein...

RaQualia elected to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia granted Durata Japanese rights to the second-generation glycopeptide antibiotic. Allergan acquired Durata in November. The drug is...